Record Growth in IsoPet® Cancer Treatments

Vivos Inc. (OTCQB: RDGL) IsoPet® animal therapies surge 150% in Q1 2025, with expanded clinics and clinical breakthroughs. Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025 | RDGL – Vivos Inc. | News | OTC Markets

Vivos Inc. has kicked off 2025 with a groundbreaking quarter, setting new records in veterinary cancer care with its IsoPet® treatment platform. The company’s unique approach continues to redefine the future of animal oncology, offering hope to pet owners nationwide.

Q1 Milestone: IsoPet® Cancer Treatments Skyrocket

The first quarter of 2025 marked a major inflection point for Vivos Inc. as the company reported a dramatic 150% increase in IsoPet® treatment volume compared to Q1 2024. A total of 15 pets were successfully treated, highlighting the platform’s accelerated adoption among veterinarians. The therapy’s single-session, outpatient design reduces hospital time and anxiety for pets, while prior treatment cases have demonstrated notable tumor shrinkage and recovery. Clinics in New Jersey and Texas led the charge in April, benefiting from a reliable biweekly yttrium-90 (Y-90) hydrogel production schedule that ensures timely availability of IsoPet® supplies.

Vivos Inc Stock Price Today | OTC RDGL Live Ticker – Investing.com

New Horizons: Equine Oncology Breakthroughs

The IsoPet® platform continues to push boundaries, particularly in the realm of equine oncology. In Q1, four horses were treated for ocular squamous cell carcinoma (SCC), a condition notorious for its sensitivity and high relapse rate. Two of these cases featured an unprecedented application of Y-90 directly into the cornea—a significant milestone in veterinary radiotherapy. These pioneering treatments build upon a proven track record, including a successful 2022 case where tumor regression was observed within three months and a 2024 case involving a ferret with notable improvement. Additional applications in palliative care and post-surgical margin treatment are showing promise in mitigating cancer recurrence in large animals.

Clinic Network Grows Across the U.S.

Access to IsoPet®’s transformative therapy widened significantly in Q1 2025 with the certification of three new clinics, raising the total to 14 across the country. These include Brazos Equine Hospital in Texas, Sumner Veterinary Hospital in Washington, and the Animal Emergency & Specialty Center in Tennessee. The expanding network now covers eight small animal clinics and six equine-focused facilities, with each staffed by professionals trained in precision Y-90 delivery. Vivos is on a mission to establish regional clinics within driving range of most pet owners, ensuring wider access to advanced cancer care by year-end.

Marketing Momentum and Community Impact

Vivos has amplified its outreach through a multi-channel marketing push that includes attendance at top veterinary conferences such as VMX in Orlando and WVC in Las Vegas. Future plans include participation at ACVIM, PacVet, VCS, and ACVS throughout the remainder of 2025. Targeted email campaigns and educational newsletters have spurred a measurable uptick in treatment inquiries. Social media engagement continues to grow, with @IsoPetForCancer actively sharing behind-the-scenes treatment stories and clinic success cases. Pet owners are increasingly sharing their testimonials, showcasing IsoPet® as a trusted, non-surgical solution.

Riding the Wave of Market Expansion

As the global veterinary oncology market—valued at $1.18 billion in 2023—heads for a projected 11.3% CAGR through 2030, IsoPet® stands positioned to seize a considerable slice of this opportunity. With an estimated 6 million new pet cancer cases annually in the U.S. alone, coupled with increasing diagnoses in exotic and large animals, demand for effective, minimally invasive treatments is on the rise. IsoPet® not only meets clinical needs but also appeals financially, with coverage by select pet insurers and a competitive cost-to-care ratio.

Leadership Outlook: Scaling and Sustainability

Dr. Michael K. Korenko, President and CEO of Vivos Inc., emphasized that the Q1 growth signals a tipping point in IsoPet®’s market presence. He noted that rising demand is fueled by positive word-of-mouth from satisfied veterinarians and pet owners, as well as growing international inquiries. The company is strategically positioning the IsoPet® division to be self-sustaining—capable of independent revenue generation and scalable growth. Dr. Korenko also expressed interest in exploring synergistic partnerships to further elevate IsoPet®’s reach and long-term viability in the veterinary oncology market.

Final Thoughts

IsoPet® isn’t just extending pet lives—it’s elevating the entire standard of care in veterinary oncology. With a growing treatment base, breakthrough use cases, and a nationwide clinic expansion strategy, Vivos Inc. is riding a wave of innovation into a future where animal cancer care is more accessible, effective, and compassionate. And yes, tails are wagging.

Vivos Inc. Announces IDE Submission for RadioGel™ (tradersque.com)

RadioGel® Technology

RadioGel® is a hydrogel liquid containing yttrium-90 phosphate microparticles, administered directly into a tumor. After injection, it gels within the tumor interstitial spaces to keep the radiation sources in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area, minimizing adverse effects on normal organs and tissues. The short half-life of RadioGel® ensures that more than 90% of its therapeutic radiation is delivered within 10 days, allowing for outpatient procedures without risk to family members.

IsoPet® for Veterinary Use

IsoPet® uses the same technology as RadioGel® for treating animals. It has been tested successfully on feline sarcoma at Washington State University and on canine soft tissue sarcomas at the University of Missouri. The FDA has classified IsoPet® as a medical device and does not require pre-market approval for veterinary use, allowing for revenue generation through sales to university hospitals and private clinics.
Vivos Inc. | RadioGel™ | IsoPet® – (OTCMKTS: RDGL)

Meet the Visionaries Behind Vivos Inc.

Meet the innovative minds driving Vivos Inc. forward in the fight against cancer. Our dedicated team combines expertise, passion, and cutting-edge technology to revolutionize cancer treatment. Learn more about our leaders and their groundbreaking work by visiting Meet The Team | RadioGel™

Disclaimer: This article includes paid promotions. We may receive compensation for promoting certain securities. This could influence our content. Please perform your own due diligence and consult with a financial advisor before making any investment decisions.